ALLMedicine™ Multiple Myeloma Center

May 23rd, 2022 - Ixazomib is an oral proteasome inhibitor approved in combination with lenalidomide and dexamethasone for the treatment of relapsed/refractory multiple myeloma (MM). Approval in the United States, Europe, and additional countries was based on resul...

May 21st, 2022 - The ubiquitin-proteasome system is the crucial homeostatic mechanism responsible for the degradation and turnover of proteins. As such, alterations at this level are often associated with oncogenic processes, either through accumulation of undegra...

May 21st, 2022 - The IKEMA study (NCT03275285) was a randomized, open-label, multicenter phase 3 study investigating isatuximab plus carfilzomib and dexamethasone (Isa-Kd) vs Kd in patients with relapsed multiple myeloma. In this subanalysis the depth of response ...

May 21st, 2022 - Tumor-associated macrophages (TAMs) are originated from circulating mononuclear cells in peripheral blood. They result from the recruitment of tumor cells and are a vital constituent of the tumor microenvironment. TAMs may be involved in the immun...

May 21st, 2022 - The delivery of bispecific antibodies (BsAbs) targeting B-cell maturation antigen (BCMA) and CD3 using the gene therapy approach is a promising alternative for BsAb administration in patients with multiple myeloma (MM). In the present study, we ev...

Jan 8th, 2022 - Clinical reactivations of herpes simplex virus or varicella zoster virus occur frequently among patients with malignancies and manifest particularly as herpes simplex stomatitis in patients with acute leukaemia treated with intensive chemotherapy ...

Dec 20th, 2021 - Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lympho...

Aug 31st, 2021 - Multiple myeloma (MM) is a hematological cancer associated with significant symptomatic burden. Bone disease, renal insufficiency, cytopenias, infection, and peripheral neuropathy, among other disease manifestations and complications, impair patie...

Feb 8th, 2021 - Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.|2021|Dimopoulos MA,Moreau P,Terpos E,Mateos MV,Zweegman S,|diagnosis,epidemiology,therapy,

Dec 8th, 2020 - Multiple myeloma is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. This manuscript discusses the management of patients with solitary plasmacytoma, smoldering multiple myeloma, ...

May 20th, 2022 - This is an open-label (identity of assigned study drug will be known) study to evaluate the safety, tolerability, and dose of daratumumab when administered in combination with various treatment regimens for different settings of multiple myeloma. ...

May 20th, 2022 - Current diagnosis of the lymphoid malignancies relies upon the morphological appearance of the cancer cells supplemented by a few molecular markers. Within a diagnostic category, the clinical courses and responses of patients to therapy are variab...

May 20th, 2022 - PRIMARY OBJECTIVES: I. To determine the maximum tolerated doses (MTD) of idasanutlin and ixazomib (ixazomib citrate) to be used in combination with dexamethasone in patients with relapsed or refractory multiple myeloma with TP53 (17p) deletion. (P...

May 20th, 2022 - Background: An estimated 79,190 people living in the United States will be diagnosed with lymphoma in 2012, including 9,060 cases of HL, 70,130 cases of non-Hodgkin s lymphoma (NHL) and multiple cases of adult T-cell leukemia/lymphoma. Laboratory ...

May 20th, 2022 - A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in participants with relapsed or refractory MM and have received 1 to 3 prior lines of therapy. Part ...

May 10th, 2022 - THE CASE A 43-year-old Black male presented to his primary care physician with an 8-month history of progressive fatigue, weakness, and unintentional weight loss. The patient’s history also included antiphospholipid antibody syndrome (APS) with pr.

May 7th, 2022 - The FDA has lifted a partial clinical hold that had been placed on studies examining magrolimab in combination with azacitidine following a review of comprehensive safety data collected from each trial, according to an announcement from Gilead Sci...

May 3rd, 2022 - Ciltacabtagene autoleucel (cilta-cel; Carvykti) demonstrated strong overall response rate (ORR) and progression-free survival (PFS) results in patients with relapsed or refractory multiple myeloma in the CARTITUDE-1 trial (NCT03548207), according ...

May 3rd, 2022 - Based on data from the phase 3 ZUMA-7 trial (NCT03391466), the FDA has approved axicabtagene ciloleucel (axi-cel; Yescarta) for the second-line treatment of adult patients with large B-cell lymphoma (LBCL) that is refractory to first-line chemoimm...

May 3rd, 2022 - This transcript has been edited for clarity. Joseph Mikhael, MD: Hello. My name is Dr Joseph Mikhael, and welcome to Medscape InDiscussion Multiple Myeloma. Today we're talking about frontline therapy for multiple myeloma, and although sometimes w...